DOP2013000169A - Compuesto para uso en el tratamiento de la artritis - Google Patents
Compuesto para uso en el tratamiento de la artritisInfo
- Publication number
- DOP2013000169A DOP2013000169A DO2013000169A DO2013000169A DOP2013000169A DO P2013000169 A DOP2013000169 A DO P2013000169A DO 2013000169 A DO2013000169 A DO 2013000169A DO 2013000169 A DO2013000169 A DO 2013000169A DO P2013000169 A DOP2013000169 A DO P2013000169A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- methyl
- arthritis
- composite
- treatment
- phenylsulfanyl
- Prior art date
Links
- 206010003246 arthritis Diseases 0.000 title abstract 2
- 239000002131 composite material Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- HPLNQCPCUACXLM-PGUFJCEWSA-N ABT-737 Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 HPLNQCPCUACXLM-PGUFJCEWSA-N 0.000 abstract 1
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98847907P | 2007-11-16 | 2007-11-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2013000169A true DOP2013000169A (es) | 2013-12-15 |
Family
ID=40291332
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2013000169A DOP2013000169A (es) | 2007-11-16 | 2013-07-23 | Compuesto para uso en el tratamiento de la artritis |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20090176785A1 (enExample) |
| EP (1) | EP2231159A1 (enExample) |
| JP (2) | JP5450434B2 (enExample) |
| KR (1) | KR101585848B1 (enExample) |
| CN (1) | CN101969951B (enExample) |
| AU (1) | AU2008322595B2 (enExample) |
| CA (1) | CA2705294C (enExample) |
| DO (1) | DOP2013000169A (enExample) |
| IL (2) | IL205501A (enExample) |
| MX (1) | MX2010005395A (enExample) |
| NZ (2) | NZ601350A (enExample) |
| RU (2) | RU2526201C2 (enExample) |
| WO (1) | WO2009064938A1 (enExample) |
| ZA (1) | ZA201003434B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100160322A1 (en) | 2008-12-04 | 2010-06-24 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| DK2550258T3 (en) | 2010-03-25 | 2015-12-07 | Abbvie Inc | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| TWI520960B (zh) | 2010-05-26 | 2016-02-11 | 艾伯維有限公司 | 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑 |
| KR20180059560A (ko) | 2010-10-29 | 2018-06-04 | 애브비 인코포레이티드 | 아폽토시스―유도제를 포함하는 고체 분산체 |
| UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
| PH12013501006A1 (en) | 2010-11-23 | 2022-03-30 | Abbvie Ireland Unlimited Co | Methods of treatment using selective bcl-2 inhibitors |
| PT2643322T (pt) | 2010-11-23 | 2017-11-13 | Abbvie Inc | Sais e formas cristalinas de um agente indutor de apoptose |
| US20140275082A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| ES2948287T3 (es) | 2017-08-23 | 2023-09-07 | Guangzhou Lupeng Pharmaceutical Company Ltd | Derivados heterocíclicos condensados como inhibidores de Bcl-2 para el tratamiento de enfermedades neoplásicas |
| US12220419B2 (en) | 2018-08-22 | 2025-02-11 | Newave Pharmaceutical Inc. | BCL-2 inhibitors |
| WO2020140005A2 (en) | 2018-12-29 | 2020-07-02 | Newave Pharmaceutical Inc. | Bcl-2 inhibitors |
| WO2021066873A1 (en) | 2019-10-03 | 2021-04-08 | Newave Pharmaceutical Inc. | Condensed heterocycles as bcl-2 inhibitors |
| PH12022551091A1 (en) | 2019-11-05 | 2024-06-24 | Abbvie Deutschland | Dosing regimens for use in treating myelofibrosis and mpn-related disorders with navitoclax |
| WO2021133817A1 (en) | 2019-12-27 | 2021-07-01 | Guangzhou Lupeng Pharmaceutical Company Ltd. | 1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases |
| AU2021228622A1 (en) | 2020-02-24 | 2022-10-13 | Guangzhou Lupeng Pharmaceutical Company Ltd. | Hot melt extruded solid dispersions containing a BCL2 inhibitor |
| US20240166646A1 (en) | 2020-12-22 | 2024-05-23 | Newave Pharmaceutical Inc. | 1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9200275D0 (en) * | 1992-01-08 | 1992-02-26 | Roussel Lab Ltd | Chemical compounds |
| WO1997013751A1 (en) * | 1995-10-10 | 1997-04-17 | Pfizer Inc. | Indole carbamates as leukotriene antagonists |
| CN1425004A (zh) * | 2000-03-21 | 2003-06-18 | 宝洁公司 | 含杂环侧链的n－取代的金属蛋白酶抑制剂 |
| HU230302B1 (hu) * | 2000-10-20 | 2015-12-28 | Eisai R&D Management Co., Ltd. | Nitrogéntartalmú aromás származékok és ezeket tartalmazó gyógyászati készítmények |
| GB0217431D0 (en) * | 2002-07-27 | 2002-09-04 | Astrazeneca Ab | Novel compounds |
| JP2007500703A (ja) * | 2003-07-28 | 2007-01-18 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ベンズイミダゾール、ベンズチアゾールおよびベンゾキサゾール誘導体およびｌｔａ４ｈモジュレーターとしてのそれらの使用 |
| EP1663979B1 (en) * | 2003-09-03 | 2013-10-09 | RaQualia Pharma Inc. | Phenyl or pyridyl amide compounds as prostaglandin e2 antagonists |
| WO2005049593A2 (en) * | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| ES2257929B1 (es) * | 2004-07-16 | 2007-05-01 | Laboratorios Del Dr. Esteve, S.A. | Derivados de pirazolina, procedimiento para su obtencion y utilizacion de los mismos como agentes terapeuticos. |
| TWI337608B (en) * | 2005-05-12 | 2011-02-21 | Abbott Lab | Apoptosis promoters |
| US20060276464A1 (en) * | 2005-05-13 | 2006-12-07 | Wyeth | Diarylsulfone sulfonamides and use thereof |
| US20080182845A1 (en) * | 2006-11-16 | 2008-07-31 | Abbott Laboratories | Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection |
-
2008
- 2008-11-14 KR KR1020107013163A patent/KR101585848B1/ko not_active Expired - Fee Related
- 2008-11-14 JP JP2010534194A patent/JP5450434B2/ja not_active Expired - Fee Related
- 2008-11-14 RU RU2012143212/15A patent/RU2526201C2/ru not_active IP Right Cessation
- 2008-11-14 AU AU2008322595A patent/AU2008322595B2/en not_active Ceased
- 2008-11-14 WO PCT/US2008/083478 patent/WO2009064938A1/en not_active Ceased
- 2008-11-14 US US12/270,987 patent/US20090176785A1/en not_active Abandoned
- 2008-11-14 NZ NZ601350A patent/NZ601350A/xx not_active IP Right Cessation
- 2008-11-14 CA CA2705294A patent/CA2705294C/en not_active Expired - Fee Related
- 2008-11-14 EP EP08850262A patent/EP2231159A1/en not_active Withdrawn
- 2008-11-14 MX MX2010005395A patent/MX2010005395A/es active IP Right Grant
- 2008-11-14 CN CN2008801242231A patent/CN101969951B/zh not_active Expired - Fee Related
- 2008-11-14 RU RU2010123796/15A patent/RU2472509C2/ru not_active IP Right Cessation
- 2008-11-14 NZ NZ585085A patent/NZ585085A/xx not_active IP Right Cessation
-
2010
- 2010-05-02 IL IL205501A patent/IL205501A/en not_active IP Right Cessation
- 2010-05-14 ZA ZA2010/03434A patent/ZA201003434B/en unknown
-
2013
- 2013-07-23 DO DO2013000169A patent/DOP2013000169A/es unknown
- 2013-07-24 IL IL227641A patent/IL227641A0/en unknown
- 2013-11-11 JP JP2013232754A patent/JP5667684B2/ja not_active Expired - Fee Related
-
2015
- 2015-12-17 US US14/972,429 patent/US20160101109A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL205501A0 (en) | 2010-12-30 |
| KR101585848B1 (ko) | 2016-01-15 |
| NZ585085A (en) | 2012-08-31 |
| MX2010005395A (es) | 2010-06-02 |
| CN101969951A (zh) | 2011-02-09 |
| CN101969951B (zh) | 2012-10-31 |
| JP2014065716A (ja) | 2014-04-17 |
| US20090176785A1 (en) | 2009-07-09 |
| NZ601350A (en) | 2013-08-30 |
| WO2009064938A1 (en) | 2009-05-22 |
| KR20100099172A (ko) | 2010-09-10 |
| RU2472509C2 (ru) | 2013-01-20 |
| ZA201003434B (en) | 2011-10-26 |
| JP2011503199A (ja) | 2011-01-27 |
| WO2009064938A9 (en) | 2009-08-06 |
| RU2010123796A (ru) | 2011-12-27 |
| CA2705294C (en) | 2016-05-17 |
| JP5450434B2 (ja) | 2014-03-26 |
| CA2705294A1 (en) | 2009-05-22 |
| RU2526201C2 (ru) | 2014-08-20 |
| EP2231159A1 (en) | 2010-09-29 |
| US20160101109A1 (en) | 2016-04-14 |
| IL205501A (en) | 2013-08-29 |
| AU2008322595A1 (en) | 2009-05-22 |
| RU2012143212A (ru) | 2014-04-20 |
| JP5667684B2 (ja) | 2015-02-12 |
| IL227641A0 (en) | 2013-09-30 |
| AU2008322595B2 (en) | 2014-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2013000169A (es) | Compuesto para uso en el tratamiento de la artritis | |
| CL2011003054A1 (es) | Forma de dosificacion solida oral de n-(4-(4-((2-(4-clorofenil)-5,5-dimetil-1-ciclohex-1-en-1-il)metil)piperazin-1-il)benzoil)-4-(((1r)-3-(morfolin-4-il)-1-((fenilsulfanil)metil)propil)amino)-3((trifluorometil)sulfonil) bencenosulfonamida; proceso para su preparacion; y su uso en desordenes proliferativos. | |
| MX2010006260A (es) | Composiciones orales de abt-263 para tratar cancer. | |
| EA201200550A1 (ru) | Фармацевтические композиции, включающие bi-1356 и метформин | |
| NZ598461A (en) | Abt-263 crystalline forms and solvates for use in treating bcl-2 protein related diseases | |
| CY1114242T1 (el) | Μια διεργασια για την παρασκευη του υποκινητη αποπτωσης αβτ-263 | |
| CL2007002930A1 (es) | Un compuesto 4-[4-({[4-cloro-3-(trifluorometil)fenil]carbamoil}amino)-3-fluorofenoxi]-n-metilpiridin-2-carboxamida monohidratado; proceso de preparacion; composicion y combinacion farmaceutica; y uso para el tratamiento de trastornos hiperproliferati | |
| BR122018014454B8 (pt) | forma cristalina sólida a do cloridrato de (-)-(1r,2r)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol | |
| CY1116312T1 (el) | Κρυσταλλος αλατος 4-(3-χλωρο-4-(κυκλοπροπυλ αμινοκαρβονυλ)αμινο-φαινοξυ)-7-μεθοξυ-6-κινολινοκαρβοξαμιδιου ή διαλυτωματος αυτου και διεργασιες για την παρασκευη αυτων | |
| CL2008000795A1 (es) | Uso de 1-[2-(2,4-dimetilfenilsulfanil)fenil)piperazina para el tratamiento del dolor o de los sintomas residuales de la depresion; y dicho compuesto. | |
| NI201700101A (es) | Composiciones farmacéuticas que comprenden n - (3, 5 - dimetoxifenil) - n'- (1-metiletil) - n - [3-(1-metil-1h-pirazol-4-il) quinoxalina-6-il]etano-1,2-diamina | |
| CL2009001936A1 (es) | Compuestos derivados de piridazina, inhibidores de 11beta-hsd1; composicion farmaceutica; procedimiento de preparacion; y uso en el tratamiento de la diabetes, obesidad, dislipidemia, trastornos de ingestion de comida e hipertension (divisional de solicitud 1720-2006). | |
| AR061481A1 (es) | Compuestos con actividad combinada sobre sert, 5-ht3 y 5-ht1a | |
| CL2007001918A1 (es) | Compuestos derivados heteroarilos sustituidos; metodo para la preparacion de los compuestos; composicion farmaceutica; y uso para el tratamiento del dolor, depresion, enfermedad de alzheimer e hipertension entre otras. | |
| CR8642A (es) | Compuestos, composiciones farmaceuticas y metodos para su uso en el tratameinto de desordenes metabolicos | |
| AR069135A1 (es) | Compuesto de alfa-(n-sulfonamido) acetamida como un inhibidor de produccion de peptido beta amiloide | |
| CY1118976T1 (el) | Κρυσταλλικες τροποποιησεις της (1r,2r)-3-(3-διμεθυλαμινο-1-αιθυλ-2-μεθυλ-προπυλ)-φαινολης | |
| NI200700068A (es) | Clorhidrato de 4-[[4-[[4-(2-cianoetenil)-2,6- dimetilfenil]amino]-2- pirimidinil]amino] benzonitrilo | |
| ECSP109890A (es) | Particulas de un antagonista de crth2 | |
| CL2008002708A1 (es) | Compuestos derivados de azaciclilisoquinolinona e isoindolinona, antagonistas de histamina-3; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuestos; y uso del compuesto para el tratamiento de un trastorno cognitivo, | |
| CL2011002233A1 (es) | Metodo para tratar o prevenir el cancer, que comprende administrar una combinacion farmaceutica sinergica de: a) (s)-n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)-6-metoxifenil)-1-(2,3-dihidroxipropil)ciclopropan-1-sulfonamida y b) 3-(6,7-bis(2-metoxietoxi)quinazolin-4-ilamino)benzonitrilo; composicion farmaceutica; y kit farmaceutico. | |
| TN2009000517A1 (en) | Amine salts of a crth2 antagonist | |
| MX388378B (es) | Compuestos de aza-indazol para usar en lesiones de tendones y/o ligamentos. | |
| CL2011003138A1 (es) | N-(protegido- n-(3-metoxi-5-metilpirazon-2-il)-2-(4-[1,3,4-oxadiazol-2-il]fenil)piridino-3-sulfonamida y su proceso de preparacion. | |
| UY39229A (es) | Formas de dosificación oral sólidas de combinación de antagonistas de la hormona liberadora de gonadotropina |